Platelet and coagulation disorders in newly diagnosed patients with pulmonary arterial hypertension

References

• Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D4–12. doi:10.1016/j.jacc.2013.10.025.
   PubMed Web of Science ®Google Scholar
• Berger G, Azzam ZS, Hoffman R, Yigla M. Coagulation and anticoagulation in pulmonary arterial hypertension. Isr Med Assoc J. 2009;11:376–379.
   PubMed Web of Science ®Google Scholar
• Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109:159–165. doi:10.1161/01.CIR.0000102381.57477.50.
   PubMed Web of Science ®Google Scholar
• Goldenberg NM, Kuebler WM. Endothelial cell regulation of pulmonary vascular tone, inflammation, and coagulation. Compr Physiol. 2015;5:531–559. doi:10.1002/cphy.c140024.
   PubMed Web of Science ®Google Scholar
• Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest. 2006;13:545–552. doi:10.1016/S0012-3692(15)51873-4.
   Google Scholar
• Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, Detre KM. Histopathology of primary pulmonary hypertension. A qualitative and 4 quantitative study of pulmonary blood vessels from 58 patients in the National heart, lung and blood institute. Circulation. 1989;80:1198–1206.
   PubMed Web of Science ®Google Scholar
• Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T, Nakanishi N. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation. 2000;102:2720–2725. doi:10.1161/01.CIR.102.22.2720.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J. 1998;12:1446–1449.
   PubMed Web of Science ®Google Scholar
• Mojadidi MK, Goodman-Meza D, Eshtehardi P, Pamerla M, Msaouel P, Roberts SC, Winoker JS, Jadeja NM, Zolty R. Thrombocytopenia is an independent predictor of mortality in pulmonary hypertension. Heart Lung. 2014;43:569–573. doi:10.1016/j.hrtlng.2014.07.006.
   PubMed Web of Science ®Google Scholar
• Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, Garcia G, Simonneau G. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med. 2001;22:451–458.
   PubMed Web of Science ®Google Scholar
• Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grünig E, Staehler G, Rosenkranz S, Halank M, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the comparative, prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA). Circulation. 2014;29:57–65. doi:10.1161/CIRCULATIONAHA.113.004526.
   Google Scholar
• Preston IE, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, Hill NS, Farber HW. Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL). Circulation. 2015;132:2403–2411. doi:10.1161/CIRCULATIONAHA.115.018435.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37:67–119. doi:10.1093/eurheartj/ehv317.
   PubMed Web of Science ®Google Scholar
• Kuiper G, Houben R, Wetzels R, Verhezen PWM, Oerle RV, Ten Cate H, Henskens YMC, Lancé MD. The use of regression analysis in determining reference intervals for low hematocrit and thrombocyte count in multiple electrode aggregometry and platelet function analyzer 100 testing of platelet function. Platelets. 2017;28:668–675. doi:10.1080/09537104.2016.1257782.
   PubMed Web of Science ®Google Scholar
• Chandrashekar V. Does platelet count in platelet-rich plasma influence slope, maximal amplitude and lag phase in healthy individuals? Results of light transmission aggregometry. Platelets. 2015;26:699–701. doi:10.3109/09537104.2015.1026318.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Steien E, Hauge B, Liseth K, Hagen KG, Størkson R, Hervig T. Thrombelastography. Transfus Apher Sci. 2009;40:119–123. doi:10.1016/j.transci.2009.01.019.
   PubMed Web of Science ®Google Scholar
• Wilkens M. Endogenous thrombin potential in practical use. Hamostaseologie. 2011;31:88–93. doi:10.5482/ha-1130.
   PubMed Web of Science ®Google Scholar
• Kirchmaier CM, Pillitter D. Diagnosis and management of inherited platelet disorders. Transfus Med Hemother. 2010;37:237–246. doi:10.1159/000316908.
   PubMed Web of Science ®Google Scholar
• Fuster V, Steele PM, Edward WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70:580–587. doi:10.1161/01.CIR.70.4.580.
   PubMed Web of Science ®Google Scholar
• Storstein O, Efskind L, Müller C, Rokseth R, Sander S. Primary pulmonary hypertension with emphasis on its etiology and treatment. Acta Med Scand. 1966;179:197–212. doi:10.1111/j.0954-6820.1966.tb05449.x.
   PubMedGoogle Scholar
• Maeda NY, Bydlowski SP, Lopes AA. Increased tyrosine phosphorylation of platelet proteins including pp125 (FAK) suggests endogenous activation and aggregation in pulmonary hypertension. Clin Appl Thromb Hemost. 2005;11:411–415.
   PubMed Web of Science ®Google Scholar
• Maeda NY, Carvalho JH, Otake AH, Mesquita SM, Bydlowski SP, Lopes AA. Platelet protease-activated receptor 1 and membrane expression of P-selectin in pulmonary arterial hypertension. Thromb Res. 2010;125:38–43. doi:10.1016/j.thromres.2009.04.018.
   PubMed Web of Science ®Google Scholar
• Varol E, Uysal BA, Ozaydin M. Platelet indices in patients with pulmonary arterial hypertension. Clin Appl Thromb Hemost. 2011;17:E171–174. doi:10.1177/1076029610394438.
   PubMed Web of Science ®Google Scholar
• Pareti FI, Capitanio A, Mannucci L, Ponticelli C, Mannucci PM. Acquired dysfunction due to the circulation of “exhausted” platelets. Am J Med. 1980;69:235–240.
   PubMed Web of Science ®Google Scholar
• Rendu F, Brohard-Bohn B. The platelet release reaction: granules’ constituents, secretion and functions. Platelets. 2011;2:261–273.
   Google Scholar
• Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, Van Vliet H. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 2006;32:589–603. doi:10.1055/s-2006-949664.
   PubMed Web of Science ®Google Scholar
• Tolga S, Hatice B, Sami I, Zeren G, Ilhan E. Comparison of mean platelet volume values among different causes of pulmonary hypertension. Cardiol J. 2012;19:180–187. doi:10.5603/CJ.
   PubMed Web of Science ®Google Scholar
• Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S. British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol. 2011;155:30–44. doi:10.1111/j.1365-2141.2011.08793.x.
   PubMed Web of Science ®Google Scholar
• Remková A, Šimková I, Valkovičová T, Kaldarárová M. Platelet abnormalities in adults with severe pulmonary arterial hypertension related to congenital heart defects (Eisenmenger syndrome). Blood Coagul Fibrinolysis. 2016;27:925–929. doi:10.1097/MBC.0000000000000523.
   PubMed Web of Science ®Google Scholar
• Aytekin M, Aulak KS, Haserodt S, Chakravarti R, Cody J, Minai OA, Dweik RA. Abnormal platelet aggregation in idiopathic pulmonary arterial hypertension: role of nitric oxide. Am J Physiol Lung Cell Mol Physiol. 2012;302:L512–520. doi:10.1152/ajplung.00289.2011.
   PubMed Web of Science ®Google Scholar
• Lee MY, Tsai KB, Hsu JH, Shin SJ, Wu JR, Yeh JL. Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways. Sci Rep. 2016;1:31788. doi:10.1038/srep31788.
   Google Scholar
• Hagan G, Pepke-Zaba J. Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds. Expert Rev Respir Med. 2011;5:163–171. doi:10.1586/ers.11.5.
   PubMed Web of Science ®Google Scholar
• Kazimierczyk R, Błaszczak P, Kowal K, Jasiewicz M, Knapp M, Szpakowicz A, Ptaszyńska-Kopczyńska K, Sobkowicz B, Waszkiewicz E, Grzywna R, et al. The significance of diminished sTWEAK and P-selectin content in platelets of patients with pulmonary arterial hypertension. Cytokine. 2018;107:52–58. doi:10.1016/j.cyto.2017.11.014.
   PubMed Web of Science ®Google Scholar
• Podda G, Femia E, Cattaneo M. Current and emerging approaches for evaluating platelet Disorders. Int Jnl Lab Hem. 2016;38(Suppl 1):50–58. doi:10.1111/ijlh.12539.
   PubMed Web of Science ®Google Scholar
• Lopes AA, Caramurú LH, Maeda NY. Endothelial dysfunction associated with chronic intravascular coagulation in secondary pulmonary hypertension. Clin Appl Thromb Hemost. 2002;8:353–358.
   PubMed Web of Science ®Google Scholar
• Robinson JC, Pugliese SC, Fox DL, Badesch DB. Anticoagulation in pulmonary arterial hypertension. Curr Hypertens Rep. 2016;18:47. doi:10.1007/s11906-016-0657-2.
   PubMed Web of Science ®Google Scholar
• Kopeć G, Moertl D, Steiner S, Stępień E, Mikołajczyk T, Podolec J, Waligóra M, Stępniewski J, Tomkiewicz-Pająk L, Guzik T, et al. Markers of thrombogenesis and fibrinolysis and their relation to inflammation and endothelial activation in patients with idiopathic pulmonary arterial hypertension. PLoS One. 2013;8:e82628. doi:10.1371/journal.pone.0082628.
   PubMed Web of Science ®Google Scholar
• Mohammed M, Fayed N, Hassanen A, Shoham D, Hou SH, Grams M. Rotational thromboelastometry and standard coagulation tests for live liver donors. Clin Transplant. 2013;27:E101–108. doi:10.1111/ctr.12122.
   PubMed Web of Science ®Google Scholar
• Tanriverdi S, Koroglu OA, Uygur O, Balkan C, Yalaz M, Kultursay N. The effect of inhaled nitric oxide therapy on thromboelastogram in newborns with persistent pulmonary hypertension. Eur J Pediatr. 2014;173:1381. doi:10.1007/s00431-014-2325-3.
   PubMed Web of Science ®Google Scholar
• Taguchi H, Kataoka M, Yanagisawa R, Kawakami T, Tamura Y, Fukuda K, Yoshino H, Satoh T. Platelet level as a new prognostic factor for idiopathic pulmonary arterial hypertension in the era of combination therapy. Circ J. 2012;76:1494–1500.
   PubMed Web of Science ®Google Scholar
• Preston J, Farber H. Anti-coagulation in pulmonary arterial hypertension: the real blood and guts. J Thorac Dis. 2016;8:E1106–1107. doi:10.21037/jtd.2016.08.48.
   PubMed Web of Science ®Google Scholar
• Hatton N, Ryan JJ. The complicated question of anticoagulation in pulmonary arterial hypertension: time to get some simple answers. Can J Cardiol. 2014;30:850e852. doi:10.1016/j.cjca.2014.08.010.
   Web of Science ®Google Scholar
• Frantz RP. Whither anticoagulation in PAH? conflicting evidence REVEALed. Circulation. 2015;132:2360–2362. doi:10.1161/CIRCULATIONAHA.115.019651.
   PubMed Web of Science ®Google Scholar
• Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J. 2006;28:999–1004. doi:10.1183/09031936.06.00015206.
   PubMed Web of Science ®Google Scholar
• Roldan T, Landzberg MJ, Deicicchi DJ, Atay JK, Waxman AB. Anticoagulation in patients with pulmonary arterial hypertension: an update on current knowledge. J Heart Lung Transplant. 2016;35:151–164. doi:10.1016/j.healun.2015.10.002.
   PubMed Web of Science ®Google Scholar
• Henkens IR, Hazenoot T, Boonstra A, Huisman MV, Vonk-Noordegraaf A. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J. 2013;41:872–878. doi:10.1183/09031936.00039212.
   PubMed Web of Science ®Google Scholar
• Roofthooft MT, Douwes JM, Vrijlandt EJ, Berger RM. Frequency and prognostic significance of hemoptysis in pediatric pulmonary arterial hypertension. Am J Cardiol. 2013;112:1505–1509. doi:10.1016/j.amjcard.2013.06.034.
   PubMed Web of Science ®Google Scholar
• Cantu J, Wang D, Safdar Z. Clinical implications of haemoptysis in patients with pulmonary arterial hypertension. Int J Clin Pract Suppl. 2012;177:5–12. doi:10.1111/ijcp.12004.
   Google Scholar